Phuturdex › Diseases › Uveitis
Drugs in development · updated 30 October 2026
Uveitis: drugs in development
As of 30 October 2026 there are 10 active clinical trials (recruiting or ongoing, phases I–III) on 10 drugs for uveitis. 6 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| FXS5626 | II | 1 | NCT07552012 |
| GenSci048 | II | 1 | NCT07547995 |
| OCS-01 | II | 1 | NCT05608837 |
| DF-003 | I | 1 | NCT06395285 |
| Laquinimod eye dropsNerventra® | I | 1 | NCT06161415 |
| TRX103 | I | 1 | NCT07427628 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AdalimumabHadlima, Simlandi® | III | 2 | NCT04088409 |
| BaricitinibOlumiant® | III | 1 | NCT04088409 |
| Oral BrepocitinibLisraya® | III | 1 | NCT06431373 |
| MinocyclineMinocyclin, Emrosi® | I–II | 1 | NCT05474729 |
Sorted by most advanced phase and number of active trials.
All 10 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Behcet Syndrome 11 drugs
- Antiphospholipid syndrome 6 drugs
- Dermatomyositis 52 drugs
- Autoimmune thrombocytopenic purpura 53 drugs
- Aneurysm 4 drugs
- Venous thrombosis 12 drugs
- Postthrombotic Syndrome 3 drugs
- Arthritis, Juvenile 39 drugs
- Cytomegalovirus Infections 6 drugs
- Myositis 42 drugs
- Immunoglobulin G4-Related Disease 14 drugs
Broader categories
- Eye disease 19 drugs
- Hereditary eye disease 4 drugs
- Retinal disease 18 drugs
- Macular degeneration 40 drugs
- Retinal degeneration 15 drugs
- Genetic disease 33 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D014605 “Uveitis”.